Matrix Capital Management Fully Exits Position in Aura Biosciences via Share Repurchase

Matrix Capital Management Company, LP, along with David E. Goel, filed Amendment No. 4 to their Schedule 13D for Aura Biosciences, Inc. (AURA) on May 11, 2026. This filing serves as an exit filing, indicating that the reporting persons no longer hold a position in the company. The liquidation of their position was triggered by a specific repurchase agreement dated April 30, 2026. Under this agreement, the Issuer (Aura Biosciences) agreed to repurchase 6,922,870 shares of Common Stock from the Matrix Fund at a price of $5.64 per share. This repurchase was contingent upon the closing of a separate equity offering by the Issuer and officially closed on May 7, 2026. Following this transaction, Matrix Capital Management and David E. Goel report 0% beneficial ownership, representing a total exit from their previous investment in the company's common stock. No other transactions were reported by the filers in the 60 days preceding this event.